BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 34957642)

  • 1. Editorial for "Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of DCE-MRI for Predicting Histological Characteristics of Breast Cancer".
    Diniz de Paula W
    J Magn Reson Imaging; 2022 Jun; 55(6):1648-1649. PubMed ID: 34957642
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiomic Analysis of Pharmacokinetic Heterogeneity Within Tumor Based on the Unsupervised Decomposition of Dynamic Contrast-Enhanced MRI for Predicting Histological Characteristics of Breast Cancer.
    Zhang L; Fan M; Wang S; Xu M; Li L
    J Magn Reson Imaging; 2022 Jun; 55(6):1636-1647. PubMed ID: 34773446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiomic features of axillary lymph nodes based on pharmacokinetic modeling DCE-MRI allow preoperative diagnosis of their metastatic status in breast cancer.
    Luo HB; Liu YY; Wang CH; Qing HM; Wang M; Zhang X; Chen XY; Xu GH; Zhou P; Ren J
    PLoS One; 2021; 16(3):e0247074. PubMed ID: 33647031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Phenotypes of Breast Cancer Heterogeneity in Preoperative Breast Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI) Scans Predict 10-Year Recurrence.
    Chitalia RD; Rowland J; McDonald ES; Pantalone L; Cohen EA; Gastounioti A; Feldman M; Schnall M; Conant E; Kontos D
    Clin Cancer Res; 2020 Feb; 26(4):862-869. PubMed ID: 31732521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiomic features of Pk-DCE MRI parameters based on the extensive Tofts model in application of breast cancer.
    Zhou X; Gao F; Duan S; Zhang L; Liu Y; Zhou J; Bai G; Tao W
    Phys Eng Sci Med; 2020 Jun; 43(2):517-524. PubMed ID: 32524436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiomic analysis of imaging heterogeneity in tumours and the surrounding parenchyma based on unsupervised decomposition of DCE-MRI for predicting molecular subtypes of breast cancer.
    Fan M; Zhang P; Wang Y; Peng W; Wang S; Gao X; Xu M; Li L
    Eur Radiol; 2019 Aug; 29(8):4456-4467. PubMed ID: 30617495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of dynamic contrast-enhanced magnetic resonance imaging and T2-weighted imaging radiomic features by a canonical correlation analysis-based feature fusion method to predict histological grade in ductal breast carcinoma.
    Fan M; Liu Z; Xie S; Xu M; Wang S; Gao X; Li L
    Phys Med Biol; 2019 Oct; 64(21):215001. PubMed ID: 31470420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour heterogeneity revealed by unsupervised decomposition of dynamic contrast-enhanced magnetic resonance imaging is associated with underlying gene expression patterns and poor survival in breast cancer patients.
    Fan M; Xia P; Liu B; Zhang L; Wang Y; Gao X; Li L
    Breast Cancer Res; 2019 Oct; 21(1):112. PubMed ID: 31623683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histogram analysis of quantitative pharmacokinetic parameters on DCE-MRI: correlations with prognostic factors and molecular subtypes in breast cancer.
    Nagasaka K; Satake H; Ishigaki S; Kawai H; Naganawa S
    Breast Cancer; 2019 Jan; 26(1):113-124. PubMed ID: 30069785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative prediction of sentinel lymph node metastasis in breast cancer by radiomic signatures from dynamic contrast-enhanced MRI.
    Liu C; Ding J; Spuhler K; Gao Y; Serrano Sosa M; Moriarty M; Hussain S; He X; Liang C; Huang C
    J Magn Reson Imaging; 2019 Jan; 49(1):131-140. PubMed ID: 30171822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative prediction of lymphovascular invasion in invasive breast cancer with dynamic contrast-enhanced-MRI-based radiomics.
    Liu Z; Feng B; Li C; Chen Y; Chen Q; Li X; Guan J; Chen X; Cui E; Li R; Li Z; Long W
    J Magn Reson Imaging; 2019 Sep; 50(3):847-857. PubMed ID: 30773770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions.
    Perre SV; Duron L; Milon A; Bekhouche A; Balvay D; Cornelis FH; Fournier L; Thomassin-Naggara I
    Eur Radiol; 2021 Jul; 31(7):4848-4859. PubMed ID: 33404696
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multi-parametric PET/MRI study of breast cancer: Evaluation of DCE-MRI pharmacokinetic models and correlation with diffusion and functional parameters.
    Inglese M; Cavaliere C; Monti S; Forte E; Incoronato M; Nicolai E; Salvatore M; Aiello M
    NMR Biomed; 2019 Jan; 32(1):e4026. PubMed ID: 30379384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and Validation of a Preoperative Magnetic Resonance Imaging Radiomics-Based Signature to Predict Axillary Lymph Node Metastasis and Disease-Free Survival in Patients With Early-Stage Breast Cancer.
    Yu Y; Tan Y; Xie C; Hu Q; Ouyang J; Chen Y; Gu Y; Li A; Lu N; He Z; Yang Y; Chen K; Ma J; Li C; Ma M; Li X; Zhang R; Zhong H; Ou Q; Zhang Y; He Y; Li G; Wu Z; Su F; Song E; Yao H
    JAMA Netw Open; 2020 Dec; 3(12):e2028086. PubMed ID: 33289845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of Noncontrast Magnetic Resonance Imaging With Diffusion-Weighted Imaging in Characterization of Breast Lesions: Intraindividual Comparison With Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
    Baltzer PAT; Bickel H; Spick C; Wengert G; Woitek R; Kapetas P; Clauser P; Helbich TH; Pinker K
    Invest Radiol; 2018 Apr; 53(4):229-235. PubMed ID: 29190227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US-localized diffuse optical tomography in breast cancer: comparison with pharmacokinetic parameters of DCE-MRI and with pathologic biomarkers.
    Kim MJ; Su MY; Yu HJ; Chen JH; Kim EK; Moon HJ; Choi JS
    BMC Cancer; 2016 Feb; 16():50. PubMed ID: 26833069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cluster analysis of quantitative parametric maps from DCE-MRI: application in evaluating heterogeneity of tumor response to antiangiogenic treatment.
    Longo DL; Dastrù W; Consolino L; Espak M; Arigoni M; Cavallo F; Aime S
    Magn Reson Imaging; 2015 Jul; 33(6):725-36. PubMed ID: 25839393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the reproducibility of a protocol for the pharmacokinetic study of breast tumors by dynamic magnetic resonance imaging.
    Etxano J; García-Lallana Valbuena A; Antón Ibáñez I; Elizalde A; Pina L; García-Foncillas J; Boni V
    Radiologia; 2015; 57(1):44-9. PubMed ID: 24525219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can imaging kinetic parameters of dynamic contrast-enhanced magnetic resonance imaging be valuable in predicting clinicopathological prognostic factors of invasive breast cancer?
    Wang C; Wei W; Santiago L; Whitman G; Dogan B
    Acta Radiol; 2018 Jul; 59(7):813-821. PubMed ID: 29105486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of breast tumor heterogeneity for ER status, HER2 status, and TN molecular subtype evaluation on DCE-MRI.
    Chang RF; Chen HH; Chang YC; Huang CS; Chen JH; Lo CM
    Magn Reson Imaging; 2016 Jul; 34(6):809-819. PubMed ID: 26968141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.